ATE340262T1 - Gruppen von borrelia burgdorferi, die lyme krankheit verursachen - Google Patents

Gruppen von borrelia burgdorferi, die lyme krankheit verursachen

Info

Publication number
ATE340262T1
ATE340262T1 AT00942966T AT00942966T ATE340262T1 AT E340262 T1 ATE340262 T1 AT E340262T1 AT 00942966 T AT00942966 T AT 00942966T AT 00942966 T AT00942966 T AT 00942966T AT E340262 T1 ATE340262 T1 AT E340262T1
Authority
AT
Austria
Prior art keywords
lyme disease
ospc
groups
borrelia burgdorferi
borrelia
Prior art date
Application number
AT00942966T
Other languages
English (en)
Inventor
Raymond J Dattwyler
Gerald Seinost
Daniel Dykhuizen
Benjamin J Luft
Maria Gomes-Solecki
Original Assignee
Univ New York State Res Found
Brook Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found, Brook Biotechnologies Inc filed Critical Univ New York State Res Found
Application granted granted Critical
Publication of ATE340262T1 publication Critical patent/ATE340262T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
AT00942966T 1999-06-18 2000-06-19 Gruppen von borrelia burgdorferi, die lyme krankheit verursachen ATE340262T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14004299P 1999-06-18 1999-06-18

Publications (1)

Publication Number Publication Date
ATE340262T1 true ATE340262T1 (de) 2006-10-15

Family

ID=22489483

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00942966T ATE340262T1 (de) 1999-06-18 2000-06-19 Gruppen von borrelia burgdorferi, die lyme krankheit verursachen

Country Status (9)

Country Link
US (2) US7060281B1 (de)
EP (2) EP1683867B1 (de)
AT (1) ATE340262T1 (de)
AU (1) AU5751000A (de)
DE (1) DE60030859T2 (de)
DK (1) DK1194559T3 (de)
ES (1) ES2272296T3 (de)
PT (1) PT1194559E (de)
WO (1) WO2000078966A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE340262T1 (de) * 1999-06-18 2006-10-15 Univ New York State Res Found Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
EP1939294A1 (de) 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Rekombinante Konstrukte von Borrelia Burgdorferi
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
WO2006014292A2 (en) * 2004-07-02 2006-02-09 Dattwyler Raymond J Oral vaccine for borrelia
AU2006320246A1 (en) 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
CN103961278A (zh) 2006-01-19 2014-08-06 玫琳凯有限公司 包括卡卡杜李提取物或巴西莓提取物的组合物
EP2155782A2 (de) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc-peptid-komplexe und anwendungen davon bei infektionskrankheiten
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2009131665A1 (en) 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
EA023290B1 (ru) 2009-08-28 2016-05-31 Мэри Кей Инк. Косметический способ и топическая композиция для омоложения, регенерации и упрочнения кожи во время сна
FR2949472B1 (fr) * 2009-08-28 2013-08-09 Biomerieux Sa Proteines utilisees pour le diagnostic d'une borreliose de lyme
US8808705B2 (en) * 2010-10-20 2014-08-19 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
US20160097768A1 (en) 2010-10-20 2016-04-07 Virginia Commonwealth University Polyvalent chimeric ospc vaccinogen and diagnostic antigen
WO2013067448A2 (en) 2011-11-03 2013-05-10 Vca Antech Inc. Compositions and methods to detect various infectious organisms
WO2013116668A2 (en) * 2012-02-01 2013-08-08 Biopeptides Corp Diagnostic peptides for lyme disease
US9562079B2 (en) 2012-04-18 2017-02-07 Zoetis Services Llc Vaccines and methods to treat lyme disease in dogs
RU2514230C1 (ru) * 2012-12-14 2014-04-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт биохимии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ биохимии" СО РАМН) Рекомбинантные химерные полипептиды, несущие эпитопы различных иммунодоминантных белков спирохет комплекса borrelia burgdorferi sensu lato, и способ серодиагностики иксодового клещевого боррелиоза
AU2015328255A1 (en) 2014-10-07 2017-04-27 The Research Foundation For The State University Of New York Recombinant Borrelia proteins and methods of use thereof
WO2017062535A2 (en) 2015-10-06 2017-04-13 Bio-Rad Laboratories, Inc. Borrelia immunoassays and materials therefor
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646016A (en) * 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
CA2157004A1 (en) 1993-02-26 1994-09-01 Cambridge Biotech Corporation Methods of inducing immunity to lyme disease and a colorimetric assay for borreliacidal activity of antisera
EP0701612B1 (de) 1993-04-29 1998-01-21 IMMUNO Aktiengesellschaft Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
CA2175567C (en) 1993-11-01 2010-08-10 John J. Dunn Chimeric proteins comprising borrelia polypeptides: uses therefor
WO1995026985A1 (en) * 1994-04-05 1995-10-12 Board Of Regents, The University Of Texas System Modified receptors that continuously signal
AR003941A1 (es) * 1995-04-19 1998-09-30 Polymun Scient Immunbilogische Forschung Gmbh Anticuerpos monoclonales humanos neutralizadores de hiv-1
US5804427A (en) * 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5683903A (en) * 1995-05-30 1997-11-04 Smithkline Beecham Corporation Attachment enhanced 293 cells
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
US5849891A (en) * 1995-07-28 1998-12-15 National Science Council Satellite RNA from bamboo mosaic virus as a vector for foreign gene expression in plants
GB9517585D0 (en) * 1995-08-29 1995-11-01 Cookson William O C Atopy diagnosis and therapy
US5756294A (en) * 1995-09-25 1998-05-26 Oncormed, Inc. Susceptibility mutation for breast and ovarian cancer
GB9526218D0 (en) * 1995-12-21 1996-02-21 Gene Shears Pty Ltd DNA Sequences
US6255464B1 (en) * 1996-04-18 2001-07-03 The Johns Hopkins University Mad-related genes in the human
CA2253374C (en) 1996-05-02 2004-07-20 Marianne Jartved Mathiesen Novel osp-c derived peptide fragments
US6110703A (en) * 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
JP4108755B2 (ja) * 1996-09-11 2008-06-25 大日本住友製薬株式会社 新規セマフォリン遺伝子：セマフォリンｙ
US6131578A (en) * 1996-10-02 2000-10-17 King; George L. Inhibitors of UDP-G1cNAc:Ga1β1-3Ga1NAcαR β1-6 N-acetylglucosaminyltransferase (core 2 G1cNAc-T) and use of the inhibitors to prevent or treat cardiomyopathy associated with diabetes
EP0970109A2 (de) 1997-03-11 2000-01-12 Genetics Institute, Inc. Sekretierte proteinen und polynukleotiden die dafür kodieren
US6420108B2 (en) * 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
DE19740735A1 (de) 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6150081A (en) * 1997-12-24 2000-11-21 Fuji Photo Film B.V. Silver halide emulsions with recombinant collagen suitable for photographic application and also the preparation thereof
CA2320806A1 (en) * 1998-02-17 1999-08-19 Institut National De La Sante Et De La Recherche Medicale Members of the d52 gene family
DK1068302T3 (da) * 1998-04-01 2005-10-03 Danisco Ikke-maltogene exoamylaser og anvendelse heraf til forsinkelse af retrogradering af stivelse
US6245525B1 (en) * 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6248937B1 (en) * 1998-04-27 2001-06-19 The Regents Of The University Of California Transcription factor and method for regulation of seed development, quality and stress-tolerance
EP1100922B1 (de) 1998-07-31 2008-02-20 Gundersen Lutheran Medical Foundation, Inc. Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff
US6627193B1 (en) * 1999-01-13 2003-09-30 University Of Georgia Research Foundation, Inc. Methods and compositions for control of blood coagulation
US6468773B1 (en) * 1999-05-19 2002-10-22 Genencor International, Inc. Mutant 1,3-propandiol dehydrogenase
ATE340262T1 (de) * 1999-06-18 2006-10-15 Univ New York State Res Found Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
US6470277B1 (en) * 1999-07-30 2002-10-22 Agy Therapeutics, Inc. Techniques for facilitating identification of candidate genes
US6472154B1 (en) * 1999-12-31 2002-10-29 Board Of Regents, The University Of Texas System Polymorphic repeats in human genes
US6337208B1 (en) * 2000-01-03 2002-01-08 Stefan Graupner Cloning vector

Also Published As

Publication number Publication date
WO2000078966A1 (en) 2000-12-28
US7060281B1 (en) 2006-06-13
EP1683867A1 (de) 2006-07-26
DE60030859T2 (de) 2007-06-14
DK1194559T3 (da) 2007-02-05
EP1683867B1 (de) 2014-04-09
AU5751000A (en) 2001-01-09
PT1194559E (pt) 2007-01-31
US20060182756A1 (en) 2006-08-17
DE60030859D1 (de) 2006-11-02
EP1194559B1 (de) 2006-09-20
US20090060932A2 (en) 2009-03-05
US7582304B2 (en) 2009-09-01
ES2272296T3 (es) 2007-05-01
EP1194559A1 (de) 2002-04-10

Similar Documents

Publication Publication Date Title
ATE340262T1 (de) Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
DE60040012D1 (de) Rekombinantes gelatin in impstoffen
ATE381575T1 (de) Veränderte borrelia burgdorferi ospa
DE60227874D1 (de) Ein Informationsverarbeitungssystem, das wirkliche Welt und virtuelle Welt nahtlos verknüpft
DE59911989D1 (de) Knochendistraktionsvorrichtung
PT1318791E (pt) Composicao farmaceutica semi-solida de isotretinoina
FR2704135B1 (fr) Agrafe d'osteosynthese.
DE69014944D1 (de) Härtbare Siloxanzusammensetzungen.
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
DE69801369D1 (de) Peptidanaloge des lh-rh, ihre verwendungen und die sie enthaltenden pharmazeutischen zusammensetzungen
CY1110961T1 (el) Πρωτεϊνη παρομοια προς νευροενδοκρινικη-ειδικη πρωτεϊνη και κωδικοποιουσα cdna
NO20073914L (no) Biologisk aktive peptider
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
DE68924601D1 (de) Reinigung von q-beta-replicase.
EP0609393A4 (en) Virulence associated proteins in -i(borrelia burgdorferi (bb)).
DE69016298D1 (de) Härtbare Organopolysiloxanzusammensetzungen.
DE59208622D1 (de) Dentalwerkstoffe auf Basis von (Meth)-Acrylaten
FR2674755B1 (fr) Nouvelles compositions medicamenteuses immunostimulatrices.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
ATE332902T1 (de) 3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika
IT1241396B (it) Composizioni tensioattive, loro preparazione e loro impiego come agenti antischiuma. (caso 150-5294)
EP0673072A3 (de) Bipolare Halbleiteranordnungen.
NL194918B (nl) SDK-peptide, en therapeutische preparaten die deze bevatten.
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
EP1865062A3 (de) Verändertes OspA der Borrelia burgdorferi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1194559

Country of ref document: EP